Bristol-Myers Squibb Company Press Releases

BMY 
$61.3
*  
0.51
0.84%
Get BMY Alerts
*Delayed - data as of Dec. 19, 2014  -  Find a broker to begin trading BMY now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27
12/17/2014 10:00:00 AM - Business Wire
▲5.76 % Price Change since this news event. The Volume Ratio is 1.4.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors
12/10/2014 6:00:00 AM - Business Wire
▲1.91 % Price Change since this news event. The Volume Ratio is 0.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb Announces Dividend
12/9/2014 4:30:00 PM - Business Wire
▲2.22 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects
12/8/2014 1:30:00 PM - Business Wire


Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma
12/6/2014 1:00:00 PM - Business Wire
▲1.32 % Price Change since this news event. The Volume Ratio is 1.17.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb Foundation Awards Nine Grants Totaling More than $3.5 Million to Support Care for High-Risk Patients with Hepatitis B and C in China and India
12/3/2014 9:00:00 AM - Business Wire
▲3.44 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb Foundation Marks World AIDS Day by Awarding $1.47 Million in New Grants to Strengthen HIV-Related Services in Five Sub-Saharan Countries
12/1/2014 9:00:00 AM - Business Wire
▲5.31 % Price Change since this news event. The Volume Ratio is 1.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb Receives Complete Response Letter from U.S. Food and Drug Administration for Daclatasvir, an Investigational Treatment for Hepatitis C
11/26/2014 11:34:00 AM - Business Wire


Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types
11/24/2014 8:59:00 AM - GlobeNewswire


Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to Advance Biopharmaceutical Innovations From Leading U.S. Academic Research Institutions
11/18/2014 2:00:00 AM - Business Wire


Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)
11/17/2014 8:00:00 AM - GlobeNewswire


Analyses from Phase IIIb Study Provide Additional Data in Earlier Use of Orencia (abatacept) Plus Methotrexate (MTX) in Citrullinated Protein (CCP)-Positive Adult Patients with Early Rheumatoid Arthritis (RA)
11/17/2014 8:00:00 AM - Business Wire


Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial
11/16/2014 3:45:00 AM - Business Wire


Bristol-Myers Squibb to Construct a New Large-Scale Biologics Manufacturing Facility in Cruiserath, Ireland
11/14/2014 6:00:00 AM - Business Wire
▲6.42 % Price Change since this news event. The Volume Ratio is 1.09.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


PURE Bioscience Updates Ongoing Sales Path for EPA Approved PURE(R) Hard Surface Disinfectant With SUBWAY(R) Restaurants and Others
11/12/2014 8:36:00 AM - Market Wire


Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting
11/12/2014 8:36:00 AM - Business Wire
▲4.55 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb Foundation Awards $2 Million in New Grants to Help Veterans and their Families Transition from Military to Civilian Life
11/10/2014 9:00:00 AM - Business Wire
▲5.11 % Price Change since this news event. The Volume Ratio is 0.7.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients
11/8/2014 9:00:00 AM - Business Wire
▲5.11 % Price Change since this news event. The Volume Ratio is 0.68.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis
11/8/2014 9:00:00 AM - Business Wire
▲5.11 % Price Change since this news event. The Volume Ratio is 0.68.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Multiple Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 56th Annual American Society for Hematology (ASH) Meeting
11/7/2014 1:44:00 PM - Business Wire
▲5.38 % Price Change since this news event. The Volume Ratio is 0.62.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb to Present at Credit Suisse 2014 Health Care Conference
11/4/2014 10:00:00 AM - Business Wire
▲5.40 % Price Change since this news event. The Volume Ratio is 0.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Insider Trading Research for Micron, Bristol-Myers Squibb, Twitter, American Realty Capital Properties, Plug Power, and GoPro
11/3/2014 8:45:00 AM - PR Newswire


Bristol-Myers Squibb Signs Exclusive Option Agreement to Acquire Galecto Biotech AB and Its Novel Galectin-3 Inhibitor in Development for Idiopathic Pulmonary Fibrosis
11/3/2014 8:30:00 AM - Business Wire
▲5.38 % Price Change since this news event. The Volume Ratio is 0.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Bristol-Myers Squibb and Lonza Expand Manufacturing Agreement
10/30/2014 1:00:00 PM - Business Wire
▲5.25 % Price Change since this news event. The Volume Ratio is 1.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology
10/30/2014 9:00:00 AM - Business Wire
▲13.50 % Price Change since this news event. The Volume Ratio is 3.47.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day